Compare Lufax Holding Ltd (LU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Medpace Holdings Inc — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 17.1× Lufax Holding Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Medpace Holdings Inc for 14 Days on average.
| LU | MEDP | |
|---|---|---|
Market Cap | $982.89M | $16.82B |
Volume | 3,323,384 | 223,093 |
Sector | Financials | Health |
52-Week High | $3.78 | $630.19 |
52-Week Low | $0.95 | $393.42 |
Typical Hold Time | 13 Days | 14 Days |
Enterprise Value | $58.81B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.95, down 3.54% on the day, with a bearish technical signal from moving averages but a bullish oscillator reading. The company reported a net loss of $2.10 billion in 2025 on revenue of $23.11 billion, with negative net income margins and ROE. A 10:1 reverse stock split occurred on October 23, 2026, and recent news highlights regulatory challenges and balance sheet strength.
The outlook remains challenged by persistent losses and revenue declines, though deep value is suggested by a P/B of 0.07 and strong parent backing. Risks include regulatory tightening in China and elevated credit costs, but analyst consensus is 69% buy with potential catalysts from capital return events.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
